Please use this identifier to cite or link to this item:
|Title:||Gadolinium deposition in the brain: summary of evidence and recommendations.|
|Authors:||Gulani, Vikas;Calamante, Fernando;Shellock, Frank G;Kanal, Emanuel;Reeder, Scott B|
|Affiliation:||Department of Radiology, Department of Urology, and Department of Biomedical Engineering, Case Comprehensive Cancer Center, Case Western Reserve University, and University Hospitals Case Medical Center, Cleveland, OH, USA|
The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia
Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia
Department of Radiology, Department of Medicine, and National Science Foundation Engineering Research Center, University of Southern California, Los Angeles, CA, USA
Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Department of Radiology, Department of Medical Physics, Department of Biomedical Engineering, Department of Medicine, and Department of Emergency Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
|Citation:||The Lancet. Neurology 2017; 16(7): 564-570|
|Abstract:||Emerging evidence has linked MRI signal changes in deep nuclei of the brain with repeated administration of gadolinium-based contrast agents. Gadolinium deposits have been confirmed in brain tissue, most notably in the dentate nuclei and globus pallidus. Although some linear contrast agents appear to cause greater MRI signal changes than some macrocyclic agents, deposition of gadolinium has also been observed with macrocyclic agents. However, the extent of gadolinium deposition varies between agents. Furthermore, the clinical significance of the retained gadolinium in the brain, if any, remains unknown. No data are available in human beings or animals to show adverse clinical effects due to the gadolinium deposition in the brain. On behalf of the International Society for Magnetic Resonance in Medicine, we present recommendations for the clinical and research use of gadolinium-based contrast agents. These recommendations might evolve as new evidence becomes available.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.